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February assays (RT-PCR) more recently. In comparison, commercially available rapid infl uenza diagnostic tests (RIDT) antigen detection 'point of care' immunoassay tests have the advantage of providing results much more quickly (within minutes). [11] [12] [13] These RIDT tests are simple to use and have the advantage of a fast turnaround, which can infl uence triage, diagnosis, initiation and duration of treatment and hospitalization. The rapid tests have a variable sensitivity ranging from 10-96%, even though the specifi city consistently exceeds >90% for some tests. [12, 13] While both molecular and POC assays have limitations for patient care, RIDTs might be useful tools during public health emergency response. During the initial phase of pandemic, a confi rmatory test was required prior to initiation of antiviral. The QuickVue Infl uenza A and B test is a POC test for rapid diagnosis of infl uenza and differentiation of infl uenza A and B viruses.
We report our fi ndings of the comparison of the QuickVue Infl uenza A and B test with that of the RT-PCR in the setting of a developing country where the volumes of patients are high and it would be greatly advantageous to have a RIDT available for quick initiation of therapy, specifi cally during pandemic periods. The study, to the best of our knowledge, is the fi rst from this part of world.
Material and Methods
All patients with infl uenza-like illness (ILI) or with severe acute respiratory illness (SARI), who were referred to the Infl uenza Clinic at Sher-i-Kashmir Institute of Medical Sciences, Srinagar, Kashmir for testing for infl uenza between September 2012 and April 2013, were enrolled for the prospective observational study for comparative diagnostic testing for infl uenza using QuickVue or RT-PCR. We defi ned ILI as fever of 100°F (>37.2  C) accompanied by cough and/or sore throat, whereas SARI was defi ned as those patients with ILI who also require hospitalisation. The timing of study was selected based on the peak circulation of infl uenza in Srinagar. [8] The specimens were either collected in an area designated for collection or from hospital wards. Combined throat and nasal swabs were collected simultaneously in viral transport medium for RT-PCR testing for infl uenza viruses. [6, 7] The lab personnel performing the RT-PCR assay were blinded to the results of the QuickVue test. QuickVue Infl uenza A and B (Quidel Corporation, San Diego, USA) is a lateral-fl ow immunoassay using highly sensitive monoclonal antibodies that are specifi c for antigens of both Infl uenza A and B virus, with no known cross reactivity to other normal fl ora or other respiratory pathogens. [14] The test involves the extraction of infl uenza A and B viral antigens. The patient specimen is placed in the 'Extraction Reagent Tube', during which time the virus particles get disrupted exposing internal viral nucleoproteins. After extraction the test strip is placed in the 'Extraction Reagent Tube' where nucleoproteins in the specimen react with the reagents in the test strip. If the extracted specimen contains infl uenza A or B antigens, a pink to red 'Test Line' along with a blue procedural 'Control Line' appears indicating a positive result. The Test Line for Infl uenza A or B develop at separate locations on the strip. In case of a negative sample, only the blue procedural Control Line will appear. [14] The QuickVue Infl uenza A and B test was carried out strictly according to the manufacturer's instructions. RT-PCR was performed within 1-3 hours of sample collection. All specimens that were infl uenza A-positive by RT-PCR were further subtyped using primers and probes for A/H1pdm09 and A/H3. Specimens positive for infl uenza A or B virus in the RT-PCR were regarded as true positives. The sensitivity, specifi city, positive (PPV) and negative (NPV) predictive values of the QuickVue Infl uenza A and B test results compared with those of the RT-PCR assay were calculated using two-by-two contingency tables. Continuous variables were tested by student's t-test, whereas categorical variables were tested for statistical signifi cance using Fisher's exact/chi-square test using Medcalc Version 12.7 software. Values have been expressed as mean + SD and a P < 0.05 was considered signifi cant.
The study was approved by the Institute Ethics Committee of SKIMS and informed consent for participation was obtained for all patients.
Results
A total of 600 patients presenting with ILI (n = 469) or SARI (n = 131) were enrolled from September 2012 to April 2013 at the tertiary care hospital at SKIMS. Among enrolled patients, almost half were males (n = 330) and 353 patients were 18 years or older. The date of enrolment ranged from 1-6 days after onset of symptoms (median 4 days).
Of the 600 recruited patients, 186 (31%) tested positive for infl uenza A or B by RT-PCR (97 for infl uenza A and 89 for infl uenza B), whereas only 43 (7.17%) tested positive for infl uenza A (n = 22, 21 were H1N1pdm09, 1 was H3N2) and infl uenza B (n = 21) by QuickVue testing. All 43 specimens positive by QuickVue were also positive by RT-PCR, thus giving a sensitivity of only 23.1% (95% confi dence interval, CI 17.3-29.8) and a specifi city of 100% (95% CI 99.1-100), with a PPV of 100% (95%CI: 91.8-100) and a NPV of 74.3% (95% CI 70.5-77.9) [ Table 1 ]. There was no difference in sensitivity of RIDT in patients with ILI (22.8; 95%CI: 16.5-30.1) or SARI (25% 95% CI: 10.7-44.9) (P = 0.67), whereas the specifi city was 100% in both the groups [ Table 1 ].
Any potential bias due to sampling or storage of kits was ruled out. All nasopharyngeal samples were collected for QuickVue and RT-PCR testing by well-trained staff members. The QuickVue kits were stored properly, not expired, and the tests were performed immediately as per the manufacturer's instructions. S28 vol. 33, Supplement 1 Analysis of QuickVue sensitivity by infl uenza types showed that there was no difference in the sensitivity for the infl uenza A and B and specifi city was 100% for both infl uenza types [ Table 2 ]. Further, both subtypes of infl uenza A/H1N1 pdm09 and A/H3 were detected by RITD assays (data not shown). We next assessed the performance of QuickVue among patients in different age groups. Of the 186 RT-PCR infl uenza positives, 51 were in those <18 years and 135 among those ≥18 years. While specifi city and PPV was 100% for both age groups, the sensitivity was higher for children <18 years (37.3%, 95% CI 24.1-51.9), compared to those in ≥18 years (17.8%; 95% CI 11.7-25.3; P < 0.009) [ Table 2 ].
When the percentage positivity of the QuickVue tests were correlated against the cycle threshold threshold (Ct), a Ct value of < 21 was associated with a near 100% positivity of the rapid test, whereas those with higher values of CT had progressively lower positivity rates [ Figure 1 ]. Thus the RT-PCR Ct values were lower in those with QuickVue test results that were positive (mean ± SD 22.02 + 3.04, range 16-31, median 22) vs negative (mean ± SD 28.35 + 3.1, range 21-35, median 28; P < 0.0001). This suggests that specimens with a higher viral load (as shown by low Ct values in the RT-PCR assay) are more likely to be positive in the QuickVue assay.
The cost of a QuickVue was approximately USD $10 per test, compared to an approximate cost of USD 50 per test for RT-PCR. The results of QuickVue are available in 15 minutes, whereas that of the RT-PCR are usually available the next day (unless during public health emergency when results are available in about 4-6 hours).
Discussion
India faced a huge public health crisis during the recent 2009 pandemic, with tremendous pressure and resource constraint on the health care system. We undertook a prospective observational analysis to compare the performance of a POC test (QuickVue) with a gold-standard RT-PCR assay to measure the utility of the POC test during public health emergencies. While we observed a very high specifi city and PPV of the QuickVue Infl uenza A and B test for detection of infl uenza A or B, the sensitivity and NPV were very low, when compared to RT-PCR in both age groups that we studied. Thus a positive QuickVue test provides a rapid confi rmation of infl uenza positivity which can help facilitate patient management and quick initiation of antiviral therapy; however, a negative test will require further assessment using more standard tests for confi rmation of infl uenza. While in India a confi rmatory test was required prior to initiation of antiviral, Centers for Disease Control (CDC) recommends that decisions about starting antiviral treatment should not await laboratory confi rmation of infl uenza. [15] Our observation of low sensitivity (23%) with high specifi city is in agreement with some other published 
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February studies. [12, 13, [16] [17] [18] [19] [20] [21] [22] [23] Overall, while the specifi city of various RITD tests is high, sensitivity varies from study to study. A recent review of 159 studies with 26 RITD assays revealed a pooled sensitivity 62.3%. [12] Some investigators have reported a higher sensitivity of RIDT when compared to viral culture. Cheng et al., [24] reported an overall sensitivity of 68% and specifi city of 96% compared with viral culture, whereas Tai et al., [25] reported a overall sensitivity of 82% and specifi city of 99%. Gordon reported an agreement of 86% between the two tests. [26] In a meta-analysis of rapid tests for infl uenza, QuickVue RIDT had the highest sensitivity (51%) of all RITDs; [13] note that the fi gure of 51% is much higher than the sensitivity in current study and may be due to characteristics of the study population. In the current study, no difference in sensitivity of detection of infl uenza A (including pandemic H1N1pdm09) and B were observed. This is in contrast to previous studies, where RITDs were shown to be more sensitive for infl uenza A than B. [18] Similar to recently reported studies, we were also able to detect pandemic A/H1N1pdm09. [27, 28] We identifi ed few factors that might account for the low sensitivity of RITDs in current study. No deviations from the manufacturer's recommended specimen type, sample storage, handling and processing were practiced and all specimens were tested immediately (within 3 hours) of collection. However, a possible mechanism for the low sensitivity could be the use of twin swabs in RT-PCR, which could lead to a higher viral load, and only a single nasopharyngeal swab in the RIDT test. The choice of a reference standard has also been reported to affect the sensitivity of the RIDT tests. For example, sensitivities have generally been higher when RIDT infl uenza tests were compared with viral culture, than when they were compared with RT-PCR. [12, 13] In the current study, we only used RT-PCR which could account for the lower measured sensitivity of detection by RIDT. The median duration of symptoms in our patients at the time of collection of swabs was 4 days (range 1-6 days). Performance of the rapid test has been reported to vary by the day of presentation, with a sensitivity of 41.7% for samples from children presenting on the day of symptom onset and a sensitivity of 72.1% for samples from children presenting one or more days post-symptom onset. [26] Thus a second swab collected after the day of the onset of the symptoms may help increase the sensitivity of the assay.
Our results emphasize that clinicians should understand that negative results of infl uenza testing do not exclude infl uenza virus infection, as a variety of factors can infl uence test results. Some of these factors include the time from the onset of illness to the collection of the specimen, prevalence of the circulating infl uenza viruses in the studied population, improper sample collection, use of clinical specimen or swab other than those recommended, prolonged time between the onset of illness and sample collection, improper storage or handling and testing of upper respiratory specimens in a patient with predominant lower respiratory disease. [5] The current study was conducted in a period of high infl uenza activity. The rate of false-negative (and true-positive) results are more likely to occur when disease prevalence is high in the community. [6] Likewise, the PPV is the highest if the activity of infl uenza is high. The high PPV of the QuickVue assay observed in this study indicates that positive results do not need to be confi rmed by RT-PCR and can be reported to the treating physician immediately in times of both low and high infl uenza rates. However, negative QuickVue Infl uenza A + B results, as well as negative results of other RIDT antigen assays, should be confi rmed by RT-PCR. This is even more important during the infl uenza season, because of decreasing NPV with increasing infl uenza virus incidence.
We observed a higher sensitivity of RITD for infl uenza detection among children as compared to adults, even as the specifi city in both age groups was similar. These observations are in agreement with previous studies where sensitivity was reported to be lower in adults when compared with children, even when adjusted for brand of RIDT, specimen type or reference standard. [18] Higher viral loads and prolonged shedding in children than in adults could contribute to the higher sensitivity seen in children. [6] Lower Ct values on RT-PCR in our patients was associated with a signifi cantly higher positivity of RIDT tests, suggesting that a higher viral load was associated with a higher positivity of the RIDT antigen test; this fi nding is similar to a recently published report. [28] The twin swabs used in the RT-PCR samples might also have yielded a higher positivity because of a higher viral load due to a greater volume of the specimen collected by two swabs as compared to one swab in the RIDT test. Recent reports suggest that there is an inverse relationship between Ct values and viral load and those therefore qualitative results from RT-PCR assays can be converted into quantitative viral load values in clinical samples without running standard curves in parallel. [29] Based on this information, we propose an alternate algorithm for infl uenza testing during a public health emergency: RIDTs can be used as a fi rst screening assay for patient management, expected to identify almost onefourth of infl uenza-positive cases. The remaining RITD negative cases should be tested by RT-PCR for infl uenza confi rmation. In addition, as RIDT-positive cases likely were detected among those with high viral loads, positive RIDT likely represent cases severe disease, [30] which can then receive immediate care and intervention. The use of RITD as fi rst line of testing can further be assessed based on the cost; the RITD cost is US$10 and the RT-PCR cost fi ve times as high. The lower cost along with a fast turnaround time argues for the use of RIDTs as the fi rst screening procedure, particularly during times of high infl uenza activity.
Our results also reinforce CDC guidelines, [15] that decisions about starting antiviral treatment should not wait for laboratory confi rmation of infl uenza. Instead, antiviral agents should be started as early as possible in patients with confi rmed or suspected infl uenza who are hospitalised; have severe, complicated, or progressive illness; or are at higher risk for infl uenza complications. [15] Antiviral agents can also be considered for other patients if treatment can be started within 48-hours of illness onset. However, clinical practice may vary among countries, and some studies show that physicians base antiviral therapy decisions on the results of infl uenza testing. In India, government response included initiation of antiviral therapy only after positive infl uenza test results. Since RIDT tests are used as rapid tests for decisions about patient management, the test provides a tool for quick confi rmation of infl uenza during public health emergency situations. Additionally, a positive RITD test would quickly indicate presence of infl uenza in population, which can help policy makers develop appropriate intervention strategies. The development of more sensitive POC rapid diagnostic tests with higher sensitivity is urgently needed.
